Sabby Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Sabby Management’s Portfolio KERX Stock Details KERX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-158	Closed	-$80K	–	384
2015 Q4	$80K	Hold	158	–	–	﹤0.01%	301
2015 Q3	$56K	Sell	158 -30	-16%	-$201	﹤0.01%	370
2015 Q2	$188K	Sell	188 -42	-18%	-$450	0.01%	300
2015 Q1	$293K	Buy	230 +102	+80%	+$1.31K	0.01%	254
2014 Q4	$181	Buy	128 +28	+28%	+$434	0.01%	215
2014 Q3	$138	Buy	+100	New	+$1.53K	0.01%	227
2014 Q2	–	Sell	-5,238	Closed	-$8.93M	–	303
2014 Q1	$8.93M	Buy	5,238 +4,646	+785%	+$70.1K	0.5%	46
2013 Q4	$767K	Sell	592 -1,689	-74%	-$20.2K	0.05%	133
2013 Q3	$2.3M	Sell	2,281 -6,929	-75%	-$61.7K	0.15%	75
2013 Q2	$6.88M	Buy	+9,210	New	+$72K	0.46%	50

Other funds holding KERX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Sabby Management's KERX Position: Q2 2015 in Review

Sabby Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q2 2015, closing a stake of 14,758 shares — an estimated $158K sold.

Sabby Management first reported a position in KERX in Q2 2013 and held it in 4 quarters. The position peaked at $5.57M in Q2 2013. 153 funds tracked by Wall St. Rank hold KERX as of Q2 2015.

Sabby Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q2 2015 after selling out during the quarter.
Sabby Management sold 14,758 Keryx Biopharmaceuticals Inc shares in Q2 2015, an estimated $158K.
Sabby Management first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 4 quarters.
Sabby Management's Keryx Biopharmaceuticals Inc position peaked at $5.57M in Q2 2013.
153 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q2 2015.

Based on Sabby Management's 13F filing for Q2 2015, filed 14 Aug 2015.